How Digital Consent Is Changing Participant Engagement
In clinical research, informed consent has traditionally been treated as a compliance requirement, a necessary step to initiate participation rather than a strategic opportunity to shape the participant experience. However, as trial designs become more complex and participant expectations evolve, this perspective is shifting. Digital consent, or eConsent, is redefining how sponsors and CROs approach […]
Preparing for Global Regulatory Submissions Starting in Phase I
The expectation that early-phase clinical trials are purely exploratory is quickly becoming outdated. Health authorities across major markets, including the U.S. Food and Drug Administration, European Medicines Agency, and Pharmaceuticals and Medical Devices Agency, are placing increasing emphasis on data quality, traceability, and global consistency from the earliest stages of development. For sponsors with global […]
Why Healthy Volunteer Retention Impacts Data Quality More Than You Think
Healthy volunteers are the backbone of many early phase clinical trials. Phase I studies, including first-in-human, bioequivalence (BE), and pharmacokinetic (PK) studies, rely on consistent participation from healthy individuals to generate reliable safety and pharmacokinetic data. While recruitment often receives the most attention during study planning, retention is just as critical to the integrity and […]
Designing First-in-Human Studies for Speed Without Sacrificing Safety
The transition from preclinical research to human testing represents one of the most critical milestones in drug development. First-in-human (FIH) studies are where theoretical promise meets clinical reality. For sponsors, these early Phase I trials must accomplish two goals simultaneously: generate high-quality safety and pharmacokinetic data while maintaining development momentum. Speed matters in today’s competitive […]
What Regulators Expect From Electronic Source Data in 2026
Electronic source, or eSource, is no longer an emerging capability in clinical research. By 2026, regulators increasingly assume that some portion of trial data will originate electronically, whether through EHR-to-EDC integration, ePRO, wearable devices, eConsent, centralized imaging platforms, or direct data entry into an eCRF. The regulatory focus has shifted from whether electronic systems are […]
The Hidden Operational Risks of Multi-Cohort Dose Escalation Studies
Multi-cohort dose escalation studies are central to early phase drug development. They generate the safety, tolerability, and pharmacokinetic (PK) insights needed to support dose progression and inform later-stage planning. While the scientific framework of these studies is well understood, their operational complexity is often underestimated. Behind every dose escalation decision sits a tightly coordinated sequence […]
Managing Protocol Amendments Without Disrupting Early Phase Timelines
Protocol amendments are an unavoidable reality in early phase clinical development. As first-in-human and early pharmacology studies progress, new safety findings, emerging pharmacokinetic data, regulatory feedback, and operational learnings often require adjustments. While amendments can strengthen study quality and protect participants, they also introduce a risk that sponsors know well: delays, budget increases, and disruption […]
A Databases Advancing Healthy Volunteer Through Inclusive Recruitment Practices
Healthy volunteer databases are foundational to early-phase clinical research, yet many remain outdated and demographically narrow. Historically, registries have drawn from limited populations, producing data that fails to reflect real-world diversity. This lack of representation undermines scientific validity and creates downstream challenges for sponsors and regulators alike. The Regulatory and Scientific Case for Diversity Inclusive […]
Strategies for Ongoing Engagement from Subjects During Clinical Trials
Recruitment is only the first hurdle in a successful clinical trial. Maintaining participant engagement and ensuring compliance throughout the study are equally critical. High dropout rates or protocol deviations can jeopardize data integrity, delay timelines, and increase costs. For early phase CROs, proactive strategies to keep subjects involved and compliant can make the difference between […]
What You Need to Know About Audit Prep
Introduction Audit readiness is no longer a reactive exercise reserved for the final stages of a clinical program. For early-phase trials, regulatory inspections and sponsor audits can occur at any point in the study lifecycle. As data integrity requirements continue to tighten and digital systems become more complex, audit preparation must be embedded into daily […]